Abstract
Thyroid cancer (THCA) is a common endocrine malignant tumor, and its global incidence of THCA has increased significantly. Neurexin 2 (NRXN2) is involved in the progression of some diseases. Nevertheless, it is still elusive towards the clinical implication and function of NRXN2 in THCA. As The Cancer Genome Atlas (TCGA) data demonstrated, we conducted a study to explore the links between NRXN2 expression and clinical features. Additionally, our data exhibited that, compared to normal thyroid tissues, NRXN2 showed low expression in THCA tissues. 20 important genes associated with NRXN2 were screened and identified. KEGG analysis data displayed that NRXN2 exhibited a link to the neuronal system, insulin secretion modulation, energy metabolism integration, muscle contraction, cardiac conduction, and neural adhesion molecule 1 (NCAM1) interactions. Our results in depth affirmed that NRXN2 was decreased in the tissues and cell lines of THCA patients. Functionally, we proved that overexpressing NRXN2 resulted in an inhibition of THCA cell proliferation, migration, and invasion in vitro. Collectively, our study demonstrated that, for the first time, NRXN2 behaved as an inhibitor of neoplasm and a promising biomarker in THCA.
Highlights
In the past 30 years, the global incidence of thyroid cancer (THCA) has increased significantly, mainly due to the increase in papillary thyroid cancer (PTC) [1, 2]
We explored the relationship between NRXN2 expression and the clinicopathological characteristics of THCA patients
NRXN1, NRXN2, and NRXN3 are three important genes of NRXNs, which is a group of presynaptic unipath transmembrane proteins and functions as the organizers of synapse in mammals
Summary
In the past 30 years, the global incidence of thyroid cancer (THCA) has increased significantly, mainly due to the increase in papillary thyroid cancer (PTC) [1, 2]. The incidence of THCA has increased rapidly, but the lethality ratio remains flat [4]. For low-risk THCA, this reduction in the degree of treatment involves the degree of surgery, including total thyroidectomy, lobectomy, or surgery without active monitoring, and indications of radioactive iodine (RAI) involved are used [5]. Molecular marker tests may help guide customized treatments for patients with thyroid nodules and THCA [6]. Preoperative risk stratification using molecular markers can be applied to better detect the most favorable scope of thyroidectomy for THCA patients [6]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Computational and mathematical methods in medicine
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
